Loading...
•
Jun 30, 2021
Zai Lab Q2 2021 Earnings Report
Zai Lab reported strong revenue growth driven by ZEJULA, Optune and QINLOCK, and entered into strategic collaborations with Mirati, MacroGenics and Schrödinger.
Key Takeaways
Zai Lab Limited announced financial results for the second quarter of 2021, reporting net product revenues of $36.9 million, compared to $11.0 million for the same period in 2020. The company reported a net loss of $163.3 million, or a loss per share attributable to common stockholders of $1.76.
Launched QINLOCK, the first product in what Zai Lab hopes will become a world-class gastric cancer franchise, in China.
Generated strong revenue growth from ZEJULA and Optune.
Entered into strategic collaborations with Mirati, MacroGenics and Schrödinger to further strengthen disease strongholds in oncology and global pipeline.
Anticipate achieving multiple regulatory milestones across product pipeline throughout 2021.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.com